The GOLD Classification is the international standard system for assessing and managing Chronic Obstructive Pulmonary Disease (COPD).
GOLD Classification for COPD
Global Initiative for Chronic Obstructive Lung Disease
What is the GOLD Classification?
The GOLD Classification is an international evidence-based guideline for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease (COPD). Developed by the Global Initiative for Chronic Obstructive Lung Disease, it provides a comprehensive framework for healthcare providers to assess and treat COPD patients.
The GOLD system has evolved over time. The current approach focuses on symptoms, exacerbation history, and comorbidities rather than solely relying on spirometric classification.
ABCD Assessment Tool
The current GOLD classification uses the ABCD assessment tool which categorizes patients into four groups (A, B, C, D) based on:
Group A
Few symptoms
Low risk
Group B
More symptoms
Low risk
Group C
Few symptoms
High risk
Group D
More symptoms
High risk
How to Determine the Group
The ABCD group is determined by evaluating:
Step 1: Symptoms
Assess using mMRC or CAT
Step 2: Risk
Based on exacerbation history or spirometry
Step 3: Group
Assign to A, B, C, or D
Components of GOLD Assessment
1. Symptom Assessment
Symptoms are evaluated using one of two validated tools:
- mMRC Dyspnea Scale (modified Medical Research Council)
- Measures breathlessness from 0 (no dyspnea) to 4 (too breathless to leave house)
- CAT (COPD Assessment Test)
- 8-item questionnaire scoring symptoms from 0-40, with higher scores indicating more severe impact
Cut-off values: mMRC ≥2 or CAT ≥10 indicates “more symptoms”
2. Risk Assessment
Risk is determined by either:
- Exacerbation history: The number of exacerbations in the past year
- Low risk: 0-1 exacerbations (not leading to hospital admission)
- High risk: ≥2 exacerbations OR ≥1 hospitalization
- Spirometric classification: If exacerbation history is unavailable
- Low risk: GOLD 1-2 (FEV1 ≥ 50%)
- High risk: GOLD 3-4 (FEV1 < 50%)
Note: Exacerbation history takes precedence over spirometry when both are available.
GOLD Spirometric Grades
While the ABCD groups guide management, spirometry still provides important prognostic information:
| GOLD Grade | Severity | FEV1 (% predicted) | Clinical Features |
|---|---|---|---|
| 1 | Mild | ≥ 80% | May be unaware of lung function impairment |
| 2 | Moderate | 50-79% | Symptoms typically develop, seeking medical attention |
| 3 | Severe | 30-49% | Worsening symptoms, repeated exacerbations |
| 4 | Very Severe | < 30% | Quality of life significantly impaired, life-threatening exacerbations |
Important: FEV1 alone is a poor descriptor of disease status. Always combine with symptom assessment and exacerbation history.
Treatment Recommendations by GOLD Group
| GOLD Group | Recommended Initial Pharmacotherapy | Non-Pharmacological Management |
|---|---|---|
| A – Low Risk, Less Symptoms | Bronchodilator (SABA or SAMA) as needed | Smoking cessation, physical activity, vaccination |
| B – Low Risk, More Symptoms | Long-acting bronchodilator (LAMA or LABA) | Smoking cessation, pulmonary rehabilitation, self-management education |
| C – High Risk, Less Symptoms | LAMA (preferred) or LABA + LAMA | Smoking cessation, pulmonary rehabilitation, exacerbation action plan |
| D – High Risk, More Symptoms | LAMA + LABA (consider adding ICS if high eosinophils) | Comprehensive pulmonary rehabilitation, oxygen if indicated, manage comorbidities |
Key: SABA = Short-acting beta-agonist, SAMA = Short-acting muscarinic antagonist, LABA = Long-acting beta-agonist, LAMA = Long-acting muscarinic antagonist, ICS = Inhaled corticosteroid
